Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Mice with two fathers have been born — and have survived to adulthood — following a complex set of experiments by a team in China.

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.